Today is the end of cycle 2 of the Lorlatinib trial for me. Each cycle is 21 days. Labs, EKGs, and oncology visits are every three weeks; MRIs and scans every six. Tomorrow will be my first scans and brain MRI since beginning the targeted therapy drug Lorlatinib (compliments Pfizer and Dana Farber Cancer Institute). After 16 glorious months on Crizotinib, it became evident that my dear friend Criz could no longer protect my noggin. But, miracle of miracles, a clinical trial appears tailor made just for my circumstances. Lorlatinib not only targets ROS1 (my cancer mutation) in the body, it treats the brain. You see, since March 2017 there has been increasing “enhancement” in my meninges on the MRIs of my brain. So, the change was made and tomorrow is the day to see how this new friend, the one with few side effects beyond making me chubby, is doing.